Welcome to our dedicated page for Gt Biopharma SEC filings (Ticker: GTBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the progress of GT Biopharma’s TriKE® cancer platform through SEC disclosures can feel like decoding lab notes. Each 10-K details complex immuno-oncology science, while 8-K reports announce pivotal Phase 1 updates the moment they reach EDGAR. If finding those nuggets inside hundreds of pages is challenging, you’re not alone.
Stock Titan’s AI engines turn every GT Biopharma SEC filing into plain-English insight. Need the latest GT Biopharma quarterly earnings report 10-Q filing without wading through accounting footnotes? Our summaries surface R&D burn rates and cash runway instantly. Wondering about GT Biopharma insider trading Form 4 transactions? Receive GT Biopharma Form 4 insider transactions real-time, complete with context on option grants and clinical milestone incentives. From the GT Biopharma annual report 10-K simplified to a GT Biopharma proxy statement executive compensation breakdown, every document is parsed, tagged and linked to the data investors ask for.
Here’s what you’ll find:
- AI-powered summaries that make understanding GT Biopharma SEC documents with AI straightforward.
- Automatic alerts when an GT Biopharma 8-K material events explained filing discloses trial results or new licensing deals.
- Side-by-side GT Biopharma earnings report filing analysis for quarter-over-quarter trend spotting.
- Direct links to GT Biopharma executive stock transactions Form 4 for pattern recognition before catalysts.
Whether you’re assessing dilution risk, monitoring NK-cell trial data, or comparing management’s stock moves to pipeline momentum, Stock Titan delivers all GTBP filings—updated in real time and explained simply—so you can focus on decisions, not document hunts.
GT Biopharma, Inc. (GTBP) filed its Q3 2025 10‑Q, reporting no revenue and a narrower net loss. The company lost $3.1 million in Q3, compared with $3.4 million a year ago, and $5.3 million for the nine months, versus $9.4 million in the prior-year period. Operating expenses fell year over year as research and development was $0.6 million and selling, general and administrative was $2.7 million in Q3. Other income was $0.3 million in Q3, helped by warrant liability revaluation.
Cash and cash equivalents were $2.53 million, total assets $4.32 million, and current liabilities $1.32 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern. Financing actions included issuing Series L 10% Convertible Preferred Stock (with dividends declared of $229,000) and establishing a committed equity facility of up to $20 million. Common shares outstanding were 6,051,874 as of September 30, 2025, and 10,636,135 as of November 6, 2025.
GT Biopharma, Inc. filed a Form 8-K announcing it furnished a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically referenced. GT Biopharma’s common stock trades on Nasdaq under the symbol GTBP.
GT Biopharma, Inc. filed a resale registration for up to 14,589,546 shares of common stock. The shares may be sold from time to time by selling stockholders and comprise 7,219,771 shares issuable upon conversion of Series L 10% Convertible Preferred Stock, 7,219,775 shares issuable upon exercise of vested warrants, and 150,000 shares issuable upon exercise of pre-funded warrants issued to an advisor.
The company will not receive proceeds from resales by the selling stockholders, though it may receive cash proceeds if vested warrants are exercised; the current warrant exercise price is $0.5319 per share. Common stock outstanding was 10,636,135 shares as of October 23, 2025, when the Nasdaq closing price was $0.73.
The filing notes beneficial ownership caps of 4.99% or 9.99% per holder. The prospectus also discloses a going concern uncertainty and outlines prior Nasdaq minimum stockholders’ equity compliance, with ongoing monitoring.
GT Biopharma director David C. Mun-Gavin acquired 31,250 shares of common stock by exercising options with a $1.33 exercise price. The reported transaction lists an acquisition of 31,250 option shares that convert to 31,250 common shares, and the filer notes the options are fully vested and exercisable.
The ownership after the reported transaction is 31,250 shares held directly. The filing is a standard Section 16 disclosure by an insider documenting option exercise and resulting beneficial ownership.
Michael Martin Breen, CEO and Director of GT Biopharma, reported three option grants on 09/04/2025 totaling 300,000 options to purchase common stock. Each option covers 100,000 shares with an exercise price of $1.33 and an expiration date of 08/19/2035. Following the reported transactions, Mr. Breen directly beneficially owns 100,000 shares for each grant (total reported underlying shares: 300,000). One grant is fully vested and exercisable; the other two vest in quarterly installments beginning 01/01/2025 and 01/01/2026 respectively. The form was signed on 09/08/2025.
Alan Urban, Chief Financial Officer of GT Biopharma, reported receipt of two stock option awards. Each option allows purchase of 50,000 shares of the company's common stock at an exercise price of $1.33 per share and lists 50,000 shares underlying each option. Both options expire on 08/19/2035. One option vests in four equal quarterly installments beginning on January 1, 2025; the other vests in four equal quarterly installments beginning on January 1, 2026. The filing reports the options as directly held by Mr. Urban and shows the reported post-transaction beneficial ownership as 50,000 shares per option line (totaling 100,000 underlying shares across both awards).
Charles J. Casamento, a director of GT Biopharma, acquired derivative securities tied to the company's common stock on 09/04/2025. The filing reports an acquisition of 62,500 options to purchase common stock with an exercise price of $1.33. The options are reported as fully vested and exercisable and are recorded as direct beneficial ownership of 62,500 underlying shares following the transaction. No cash price for the underlying shares is reported in the filing and no other transactions or dispositions are included.
Hilary Kramer, a director of GT Biopharma, Inc. (GTBP), exercised options to acquire 31,250 shares of common stock on 09/04/2025 at an exercise price of $1.33 per share. The options are reported as fully vested and exercisable, and following the transaction Ms. Kramer directly beneficially owns 31,250 shares. The Form 4 was signed by the reporting person and reflects a single option exercise converting derivative securities into common stock.
FAQ
What is the current stock price of Gt Biopharma (GTBP)?
What is the market cap of Gt Biopharma (GTBP)?
